RG
Redmile Group Portfolio holdings
AUM
$940M
1-Year Return
75.78%
This Quarter Return
-3.89%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.3B
AUM Growth
-$140M
(-5.7%)
Cap. Flow
+$111M
Cap. Flow
% of AUM
4.81%
Top 10 Holdings %
Top 10 Hldgs %
42.59%
Holding
80
New
11
Increased
12
Reduced
36
Closed
4
Top Buys
| 1 |
CTLT
CATALENT, INC.
CTLT
|
$40.1M |
| 2 |
DexCom
DXCM
|
$39M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$32.6M |
| 4 |
Sarepta Therapeutics
SRPT
|
$31.9M |
| 5 |
Bristol-Myers Squibb
BMY
|
$31.2M |
Top Sells
| 1 |
ONEM
1Life Healthcare, Inc. Common Stock
ONEM
|
$38.9M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$37M |
| 3 |
Pliant Therapeutics
PLRX
|
$25.3M |
| 4 |
Akero Therapeutics
AKRO
|
$22.5M |
| 5 |
Amicus Therapeutics
FOLD
|
$21.1M |
Sector Composition
| 1 | Healthcare | 98.78% |
| 2 | Industrials | 1.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Bristol-Myers Squibb
BMY
$95B
| $31.2M | 1.35% |
+449,442
| New | +$31.2M |
|
27
Regenxbio
RGNX
$477M
| $31M | 1.35% |
1,640,725
-272,787
| -14% | -$5.16M |
|
|
IMGN
28
DELISTED
Immunogen Inc
IMGN
| $30.9M | 1.34% |
8,046,217
-486,600
| -6% | -$1.87M |
|
29
Elevance Health
ELV
$69.4B
| $30.5M | 1.32% |
66,398
+27,428
| +70% | +$12.6M |
|
30
Ventyx Biosciences
VTYX
$185M
| $27.3M | 1.19% |
815,774
-79,200
| -9% | -$2.65M |
|
31
Entrada Therapeutics
TRDA
$199M
| $26.6M | 1.15% |
1,831,608
-22,500
| -1% | -$326K |
|
32
ADC Therapeutics
ADCT
$386M
| $26.5M | 1.15% |
13,565,249
+5,974,400
| +79% | +$11.7M |
|
33
Humana
HUM
$37.5B
| $25.3M | 1.1% |
+52,079
| New | +$25.3M |
|
|
AUGX
34
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $25M | 1.09% |
14,380,327
| – | – |
|
35
Scholar Rock
SRRK
$3.12B
| $25M | 1.08% |
3,124,226
+1,028,406
| +49% | +$8.23M |
|
36
Repare Therapeutics
RPTX
$73M
| $24.9M | 1.08% |
2,533,050
-151,346
| -6% | -$1.49M |
|
37
Prime Medicine
PRME
$606M
| $24.5M | 1.06% |
1,992,843
-216,507
| -10% | -$2.66M |
|
38
Nurix Therapeutics
NRIX
$697M
| $24.4M | 1.06% |
2,749,384
-251,400
| -8% | -$2.23M |
|
39
Stevanato
STVN
$6.29B
| $23.4M | 1.01% |
901,932
-40,593
| -4% | -$1.05M |
|
40
Charles River Laboratories
CRL
$8B
| $23.3M | 1.01% |
+115,328
| New | +$23.3M |
|
41
Immunovant
IMVT
$2.81B
| $20.4M | 0.89% |
1,317,031
+228,900
| +21% | +$3.55M |
|
|
GRTS
42
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $19.3M | 0.84% |
6,926,926
-4,534
| -0.1% | -$12.6K |
|
43
Centene
CNC
$14.1B
| $17.5M | 0.76% |
277,351
-3,909
| -1% | -$247K |
|
44
Shattuck Labs
STTK
$72.3M
| $16.5M | 0.72% |
5,619,914
| – | – |
|
45
Atara Biotherapeutics
ATRA
$89.1M
| $16.3M | 0.71% |
224,482
-25,228
| -10% | -$1.83M |
|
|
VERV
46
DELISTED
Verve Therapeutics
VERV
| $16.2M | 0.7% |
1,120,679
-101,224
| -8% | -$1.46M |
|
47
IQVIA
IQV
$31.3B
| $14.3M | 0.62% |
+71,657
| New | +$14.3M |
|
48
Absci
ABSI
$359M
| $14.1M | 0.61% |
8,031,094
| – | – |
|
49
89bio
ETNB
$1.28B
| $13.7M | 0.59% |
+900,000
| New | +$13.7M |
|
50
Annexon
ANNX
$236M
| $13.5M | 0.59% |
3,503,190
| – | – |
|